CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Guizhou Bailing Group Pharmaceutical Company Limited Company Snapshot
Guizhou Bailing Group Pharmaceutical Company Limited operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Guizhou Bailing Group Pharmaceutical Company Limited with three other companies in this sector in China: Hunan Jingfeng Pharmaceutical Co Ltd (2017 sales of 2.58 billion Chinese Renmimbi [US$376.52 million] of which 97% was Medicine Manufacturing), SSY Group Ltd (2.66 billion Chinese Renmimbi [US$387.36 million] of which 96% was Intravenous Infusion Solution and Others), and Anhui Fengyuan Pharmaceutical (2.58 billion Chinese Renmimbi [US$375.71 million] of which 58% was Medicine Retail Circulation).

Sales Analysis. During the year ended December of 2017, sales at Guizhou Bailing Group Pharmaceutical Company Limited were 2.59 billion Chinese Renmimbi (US$377.71 million). This is an increase of 17.1% versus 2016, when the company's sales were 2.21 billion Chinese Renmimbi. This was the fifth consecutive year of sales increases at Guizhou Bailing Group Pharmaceutical Company Limited (and since 2012, sales have increased a total of 90%). Sales of Medical Institution saw an increase that was more than double the company's growth rate: sales were up 39.3% in 2017, from 52.28 million Chinese Renmimbi to 72.84 million Chinese Renmimbi. Not all segments of Guizhou Bailing Group Pharmaceutical Company Limited experienced an increase in sales in 2017: sales of Business fell 27.9% to 167.50 million Chinese Renmimbi. Guizhou Bailing Group Pharmaceutical Company Limited also experienced decreases in sales in Other (down 16.3% to 10.15 million Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Guizhou Bailing Group Pharmaceutical Company Limited
  Stock Performance Chart for Guizhou Bailing Group Pharmaceutical Company Limited
 
  Stock Data: Recent Stock Performance:
  Current Price (9/14/2018): 9.19
(Figures in Chinese Renmimbi)
1 Week -0.5%   13 Weeks -6.8%  
4 Weeks -25.9%   52 Weeks -45.6%  
 
Guizhou Bailing Group Pharmaceutical Company Limited Key Data:
  Ticker: 002424 Country: China
  Exchanges: SZN Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2017 Sales 2,591,816,650
(Year Ending Jan 2018).
Employees: 5,456
  Currency: Chinese Renmimbi Market Cap: 12,968,928,000
  Fiscal Yr Ends: December Shares Outstanding: 1,411,200,000
  Share Type: A Gu Closely Held Shares: 1,029,092,200
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.